Overview
- The Court’s order, issued Thursday, keeps teleprescription, postal delivery, and pharmacy pickup of mifepristone in place nationwide while the justices decide whether to take the case.
- A May 1 appellate ruling had temporarily blocked mailing of the drug, prompting emergency filings from manufacturers Danco and GenBioPro that warned of immediate confusion for pharmacies, clinics, distributors, and patients.
- Justices Samuel Alito and Clarence Thomas publicly disagreed with continuing the stay, signaling clear division on the Court.
- Advocates say access still faces a separate risk because the FDA has begun a new safety review of mifepristone under political pressure, which could tighten rules even without a court ruling.
- Medication abortion accounts for nearly two-thirds of U.S. abortions, and many patients in restrictive states rely on telehealth from protective states and mail delivery to avoid in‑person visits that are hard to obtain.